Advice

in the absence of a submission from the holder of the marketing authorisation:

brentuximab vedotin (Adcetris®) is not recommended for use within NHSScotland.

Indication under review: Treatment of adult patients with CD30+ Hodgkin lymphoma at increased risk of relapse or progression following autologous stem cell transplant.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

Download detailed advice135KB (PDF)

Download

Medicine details

Medicine name:
brentuximab vedotin (Adcetris)
SMC ID:
SMC2085
Indication:
Treatment of adult patients with CD30+ Hodgkin lymphoma at increased risk of relapse or progression following autologous stem cell transplant.
Pharmaceutical company
Takeda UK Ltd
BNF chapter
Submission type
Non submission
Status
Not recommended
Date advice published:
07 May 2018